Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 3, 2009

Champions Biotechnology Signs On Gradalis to Develop Personalized Cancer Vaccines

  • Champions Biotechnology has established a collaboration with Gradalis and Mary Crowley Cancer Research Center (MCCRC) to develop personalized vaccines for cancer patients. Gradalis will work toward the IND that is required to begin administering the individualized vaccine to patients at MCCRC in a Phase I trial.

    The team will use Champions Biotechnology’s Biomerk Tumorgraft™ technology, which engineers vaccines based on each patient’s tumor. “The close correlation between Biomerk Tumorgrafts™ and the human tumor they are derived from provide the basis for our predictive preclinical platform,” explains Doug Burkett, Ph.D., president of Champions Biotechnology.

    “This technology also enables us, in collaboration with Gradalis, to develop personalized vaccines for cancer patients. Personalized vaccines offer a novel treatment option that is customized to each individual’s unique cancer but can rarely be produced due to insufficient cells from accessible tumor tissue.”

    ---

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »